Webinar: Incorporating Immunotherapy for Patients with Operable Esophageal and GE Junction Adenocarcinomas

October 10, 2025

Our Presenter

Samuel J. Klempner, M.D.

Dr. Klempner is a Medical Oncologist and Associate Professor at Massachusetts General Hospital and Harvard Medical School. He leads the Gastric and Esophageal program where he works in a multidisciplinary team to optimize and individualize treatment using molecular characterization across all stages of GI cancers.  He conducts clinical trials and translational research with new targeted agents and immune therapies, and is active in the gastroesophageal cancer community.

His clinical and translational research is centered on cancer genomics, acquired resistance to targeted therapies, and the intersection of genomics and immune-mediated therapies to identify novel therapeutic approaches and biomarkers in gastroesophageal cancers. His work has been published in multiple journals including Journal of Clinical Oncology (JCO), Cancer Discovery, Lancet Oncology, JAMA Oncology, Annals of Oncology and others.   He is an active member of the ASCO TAPUR trial molecular tumor board and serves on the editorial board of JCO Precision oncology.

Please take two minutes to complete this short survey to give us your feedback about the webinar.

Slides from Dr. Klempner’s presentation will be available here after 10/26/25

Generous Sponsors that make ECAN’s Webinar Series possible